Document Detail

The responsiveness and validity of the CAMPHOR Utility Index.
MedLine Citation:
PMID:  18768576     Owner:  NLM     Status:  MEDLINE    
The aim of the present study was to validate and determine the minimal important difference (MID) and responsiveness of the Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR) Utility Index, a new tool enabling cost utility analyses. CAMPHOR, 6-min walking test (6MWT) and New York Heart Association (NYHA) data for 869 pulmonary hypertension patients (545 (63%) female; mean+/-SD age 56.6+/-15.4 yrs) from three centres were analysed. Utility was correlated with 6MWT data and calculated by NYHA class to assess validity. Effect sizes were calculated for those with two CAMPHOR assessments. Distribution and anchor-based MIDs were calculated. Analyses were carried out in patients receiving bosentan in order to determine whether or not those remaining in NYHA class III following treatment improved. The Utility Index distinguished between adjacent NYHA classes and correlated with 6MWT results. CAMPHOR subscales and utility were as responsive as the 6MWT (effect sizes ranged 0.31-0.69 for the CAMPHOR and 0.16-0.34 for the 6MWT). The within-group MID for the Utility Index was estimated to be approximately 0.09. Patients remaining in NYHA class III experienced, on average, a significant improvement (CAMPHOR Utility Index and functioning), which exceeded the MID. The CAMPHOR Utility Index is valid and responsive to change. Patients can experience significant and important improvements even if they do not improve on the basis of traditional outcomes, such as NYHA functional class.
D M Meads; S P McKenna; N Doughty; C Das; W Gin-Sing; J Langley; J Pepke-Zaba
Related Documents :
15318696 - The role of modern matrons in raising standards of infection control.
16374176 - Intensive care unit quality improvement: a "how-to" guide for the interdisciplinary team.
8673786 - Research directions conference: research directions in emergency medicine. january 20-2...
17411926 - Pay for performance: pay more or pay less?
17920646 - The effect of season and weather on physical activity: a systematic review.
24885746 - Facilitating professional liaison in collaborative care for depression in uk primary ca...
Publication Detail:
Type:  Journal Article; Multicenter Study     Date:  2008-09-03
Journal Detail:
Title:  The European respiratory journal     Volume:  32     ISSN:  1399-3003     ISO Abbreviation:  Eur. Respir. J.     Publication Date:  2008 Dec 
Date Detail:
Created Date:  2008-12-01     Completed Date:  2009-05-08     Revised Date:  2013-06-18    
Medline Journal Info:
Nlm Unique ID:  8803460     Medline TA:  Eur Respir J     Country:  Switzerland    
Other Details:
Languages:  eng     Pagination:  1513-9     Citation Subset:  IM    
Galen Research, Enterprise House, Manchester Science Park, Manchester, M15 6SE, UK.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antihypertensive Agents / pharmacology
Cost-Benefit Analysis
Exercise Test
Great Britain
Hypertension, Pulmonary / classification*,  diagnosis*
Middle Aged
Quality of Life
Reproducibility of Results
Severity of Illness Index*
Sulfonamides / pharmacology
Reg. No./Substance:
0/Antihypertensive Agents; 0/Sulfonamides; Q326023R30/bosentan

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Reference values for cardiopulmonary exercise testing in healthy volunteers: the SHIP study.
Next Document:  Impact of macrolide therapy on mortality for patients with severe sepsis due to pneumonia.